We are live on
!
Find out more
LC
Lindbrook Capital Portfolio holdings
AUM
$1.08B
1-Year Est. Return
10.14%
This Fund
S&P 500
This Quarter
Est. Return
+7.65%
1 Year Est. Return
+10.14%
3 Year Est. Return
+35.77%
5 Year Est. Return
+141.26%
10 Year Est. Return
–
AUM
$939M
AUM Growth
+$86.2M
(+10%)
Cap. Flow
+$29.6M
Cap. Flow
% of AUM
3.15%
Top 10 Holdings %
Top 10 Hldgs %
46.18%
Holding
2,925
New
150
Increased
988
Reduced
857
Closed
215
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Total International Stock ETF
VXUS
|
+$5.37M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$3.7M |
| 3 |
Vanguard Morningstar Total Stock Market ETF
VTI
|
+$2.54M |
| 4 |
Invesco QQQ Trust
QQQ
|
+$2.12M |
| 5 |
NVIDIA
NVDA
|
+$1.88M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$6.88M |
| 2 |
State Street Consumer Staples Select Sector SPDR ETF
XLP
|
+$4.62M |
| 3 |
Oaktree Specialty Lending
OCSL
|
+$825K |
| 4 |
MGI
MoneyGram International, Inc. New
MGI
|
+$627K |
| 5 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$562K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.18% |
| 2 | Technology | 15.3% |
| 3 | Healthcare | 6.27% |
| 4 | Consumer Discretionary | 3.61% |
| 5 | Industrials | 3.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2276
Babcock & Wilcox
BW
$1.39B
| $1.45K | ﹤0.01% |
245
| – | – |
|
2277
NETGEAR
NTGR
$635M
| $1.44K | ﹤0.01% |
102
+77
| +308% | +$1.16K |
|
2278
Ligand Pharmaceuticals
LGND
$6.36B
| $1.44K | ﹤0.01% |
20
| – | – |
|
2279
Franklin Electric
FELE
$4.84B
| $1.44K | ﹤0.01% |
14
| – | – |
|
|
TARO
2280
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $1.44K | ﹤0.01% |
38
-75
| -66% | -$2.35K |
|
|
NTST
2281
NETSTREIT Corp
NTST
$2.1B
| $1.43K | ﹤0.01% |
80
| – | – |
|
2282
Olema Pharmaceuticals
OLMA
$1.05B
| $1.43K | ﹤0.01% |
+158
| New | +$954 |
|
2283
Omeros
OMER
$959M
| $1.43K | ﹤0.01% |
+262
| New | +$1.53K |
|
2284
Amalgamated Financial
AMAL
$1.49B
| $1.42K | ﹤0.01% |
88
-74
| -46% | -$1.19K |
|
2285
Atea Pharmaceuticals
AVIR
$420M
| $1.41K | ﹤0.01% |
378
+67
| +22% | +$251 |
|
2286
LivePerson
LPSN
$32.3M
| $1.41K | ﹤0.01% |
+21
| New | +$1.36K |
|
2287
Kenvue
KVUE
$36.9B
| $1.4K | ﹤0.01% |
+53
| New | +$1.38K |
|
2288
Matsons
MATX
$6.18B
| $1.4K | ﹤0.01% |
18
+14
| +350% | +$960 |
|
2289
GFL Environmental
GFL
$14.9B
| $1.4K | ﹤0.01% |
36
+24
| +200% | +$872 |
|
2290
Cass Information Systems
CASS
$743M
| $1.4K | ﹤0.01% |
36
-138
| -79% | -$5.42K |
|
2291
Scholar Rock
SRRK
$6.44B
| $1.4K | ﹤0.01% |
+185
| New | +$1.4K |
|
|
JWN
2292
DELISTED
Nordstrom
JWN
| $1.39K | ﹤0.01% |
68
+53
| +353% | +$891 |
|
|
TDAY
2293
USA Today Co
TDAY
$1.06B
| $1.39K | ﹤0.01% |
+618
| New | +$1.23K |
|
|
CHCT
2294
Community Healthcare Trust
CHCT
$454M
| $1.39K | ﹤0.01% |
42
+14
| +50% | +$487 |
|
|
LTC
2295
LTC Properties
LTC
$2.15B
| $1.39K | ﹤0.01% |
42
+17
| +68% | +$568 |
|
2296
SouthState Bank Corp
SSB
$10.5B
| $1.38K | ﹤0.01% |
21
-77
| -79% | -$5.14K |
|
2297
Invesco Mortgage Capital
IVR
$805M
| $1.38K | ﹤0.01% |
120
-840
| -88% | -$8.98K |
|
2298
Blue Owl Capital
OWL
$18.5B
| $1.38K | ﹤0.01% |
118
-39
| -25% | -$420 |
|
2299
Plexus
PLXS
$7.23B
| $1.38K | ﹤0.01% |
14
-23
| -62% | -$2.11K |
|
2300
Ameris Bancorp
ABCB
$5.89B
| $1.37K | ﹤0.01% |
40
| – | – |
|
Similar funds
SBIA
CHP
MW
TAM
SIA
CIG
CCM
WCF
Lindbrook Capital's Q2 2023 Portfolio in Review
As of Q2 2023, Lindbrook Capital held 2,925 positions worth $939M, up 10% from $853M the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Lindbrook Capital deployed $29.6M of net new capital in Q2 2023, opening 150 new positions and adding to 988 existing holdings. Its largest new stake was UPAR Ultra Risk Parity ETF: 21,000 shares worth $291K.
By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 17% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Vertex Pharmaceuticals, an estimated $6.88M trimmed.
- Lindbrook Capital's largest Q2 2023 buy was UPAR Ultra Risk Parity ETF: 21,000 shares worth $291K.
- Lindbrook Capital added most to Vanguard Total International Stock ETF in Q2 2023, an estimated $5.37M increase.
- Lindbrook Capital's biggest Q2 2023 reduction was Vertex Pharmaceuticals, cutting an estimated $6.88M.
- Lindbrook Capital fully exited MoneyGram International, Inc. New in Q2 2023, selling an estimated $627K.
- Lindbrook Capital's ten largest holdings make up 46% of its $939M portfolio in Q2 2023.
- Lindbrook Capital opened 150 new positions and closed 215 in Q2 2023.
- Lindbrook Capital's portfolio value rose 10% quarter-over-quarter to $939M.
Based on Lindbrook Capital's 13F filing for Q2 2023, filed 31 Jul 2023.